Showing 961 - 980 results of 3,189 for search '"vaccines"', query time: 0.07s Refine Results
  1. 961
  2. 962

    N-Terminal Plasmodium vivax Merozoite Surface Protein-1, a Potential Subunit for Malaria Vivax Vaccine by Fernanda G. Versiani, Maria E. Almeida, Luis A. Mariuba, Patricia P. Orlandi, Paulo A. Nogueira

    Published 2013-01-01
    “…The lack of in vitro cultures for P. vivax represents a major delay in developing a functional malaria vaccine. One of the major candidates to antimalarial vaccine is the merozoite surface protein-1 (MSP1), which is expressed abundantly on the merozoite surface and capable of activating the host protective immunity. …”
    Get full text
    Article
  3. 963

    The Adoption Process to Technology Biosecurity and Vaccination in the Dispersal of Foot and Mouth Disease Bone Regency, South Sulawesi Province by Rismayanti Rismayanti

    Published 2025-01-01
    “… Adopting biosecurity and vaccination technology is one of the steps that can be taken to overcome and minimize FMD disease in beef cattle farming. …”
    Get full text
    Article
  4. 964

    Ecological study of the association between the English national vaccination programme and area deprivation inequalities in COVID-19 mortality by Clare Bambra, Adam Todd, Fiona Matthews, David Sinclair, Natalie Bennett

    Published 2025-01-01
    “…However, more could be achieved if barriers to vaccination uptake in the most deprived areas are overcome.…”
    Get full text
    Article
  5. 965

    The immunogenicity of PRV ΔgE/TK/UL49.5 three-gene-deleted vaccine in mice by Chenmeng Ding, Yawei Sun, Xianfeng Zhang, Mengmeng Shi, Han Yang, Xin Zhou, Shuangshuang Li, Yongtao Li, Xia Yang, Linyang Yu, Lu Chen

    Published 2025-02-01
    “…Abstract Background Pseudorabies (PR) caused by the re-emerging of pseudorabies virus (PRV) variant has outbroken among PRV vaccine immunized swine in many pig farms, which has caused serious social and economic consequences since the end of 2011. …”
    Get full text
    Article
  6. 966
  7. 967

    A Case Report of DVT following the Johnson and Johnson Vaccine against the Novel SARS-CoV-2 by Ayrton Bangolo, Jeffin Cherian, Mohamed Ahmed, Ali Atoot, Bhavna Gupta, Adam Atoot

    Published 2022-01-01
    “…In this case report, we present a female who developed a DVT four days after receiving the J&J vaccine. We propose that the administration of this vaccine may further increase the risk of developing DVTs in patients with previous risk factors, and we hope to use this case to support screening all patients for previous risk factors for thrombosis before administration of the J&J vaccine.…”
    Get full text
    Article
  8. 968
  9. 969
  10. 970
  11. 971

    Regional disparities of full pentavalent vaccine uptake and the determinants in Ethiopia: Mapping and spatial analysis using the EDHS data. by Getasew Mulat Bantie, Melaku Tadege, Teshager Zerihun Nigussie, Ashenafi Abate Woya, Abay Kassa Tekile, Amare Alemu Melese, Simeneh Ayalew, Belay Bezabih Beyene, Gizachew Yismaw Wubetu

    Published 2025-01-01
    “…<h4>Result</h4>The national full pentavalent vaccine uptake was 59.2%. The spatial distribution of full pentavalent vaccine uptake was not uniform in Ethiopia. …”
    Get full text
    Article
  12. 972
  13. 973

    Acute Myopericarditis after the Second Dose of mRNA COVID-19 Vaccine Mimicking Acute Coronary Syndrome by Chris Pantsios, Zacharias-Alexandros Anyfantakis, Andrew Xanthopoulos, Ioannis Leventis, Spyridon Skoularigkis, Apostolos Dimos, Angeliki Bourazana, Michail Papamichalis, Grigorios Giamouzis, Filippos Triposkiadis, John Skoularigis

    Published 2022-01-01
    “…Myocarditis is a rare adverse event of vaccination. Recently, mRNA vaccines for COVID-19 have been reported to correlate with myocarditis, specifically in adolescents and young men. …”
    Get full text
    Article
  14. 974

    Effects of community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trial. by Anna Roca, Philip C Hill, John Townend, Uzo Egere, Martin Antonio, Abdoulie Bojang, Abiodun Akisanya, Teresa Litchfield, David E Nsekpong, Claire Oluwalana, Stephen R C Howie, Brian Greenwood, Richard A Adegbola

    Published 2011-10-01
    “…<h4>Background</h4>Introduction of pneumococcal conjugate vaccines (PCVs) of limited valency is justified in Africa by the high burden of pneumococcal disease. …”
    Get full text
    Article
  15. 975
  16. 976

    Vaccination with Enzymatically Cleaved GPI-Anchored Proteins from Schistosoma mansoni Induces Protection against Challenge Infection by Vicente P. Martins, Carina S. Pinheiro, Barbara C. P. Figueiredo, Natan R. G. Assis, Suellen B. Morais, Marcelo V. Caliari, Vasco Azevedo, William Castro-Borges, R. Alan Wilson, Sergio C. Oliveira

    Published 2012-01-01
    “…Current schistosomiasis control strategies are mainly based on chemotherapy, but many researchers believe that the best long-term strategy to control schistosomiasis is through immunization with an antischistosomiasis vaccine combined with drug treatment. In the search for potential vaccine candidates, numerous tegument antigens have been assessed. …”
    Get full text
    Article
  17. 977
  18. 978
  19. 979
  20. 980